<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Concern/Parkinsons_Disease.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:31:06 GMT -->
<head>
<meta http-equiv="Content-Type" content="text/html; charset=ISO-8859-1">
<meta name="Language" content="es">
<meta name="ContentID" content="1244009">
<meta name="Category" content="Concern">
<meta name="Article" content="Parkinsons_Disease">
<title>Enfermedad de Parkinson-Referencias</title>
<link type="text/css" rel="stylesheet" href="../Styles/hnqrHtml.css">
<base target="_self">
</head>
<body>
<div id="Article-Title" class="Article-Title"><a name="Article-Title"></a> 

<p class="Article-Title">Enfermedad de Parkinson</p>
</div>

<div id="Reference-List" class="Reference-List">
<p class="Reference-Autofill"><a href="Parkinsons_Disease.htm">Volver al
art&#237;culo.</a></p>

<h3>Referencias para el art&#237;culo</h3>

<ol class="Reference-List">
<li class="Ref">Karstaedt PJ, Pincus JH. Protein redistribution diet remains effective in
patients with fluctuating parkinsonism. <em>Arch Neurol</em> 1992;49:149&#8211;51.</li>

<li class="Ref">Carter JH, Nutt JG, Woodward WR, et al. Amount and distribution of dietary
protein affects clinical response to levodopa in Parkinson&#8217;s disease. <em>Neurology</em>
1989;39:552&#8211;6.</li>

<li class="Ref">Pincus JH, Barry KM, Dietary method for reducing fluctuations in
Parkinson&#8217;s disease. <em>Yale J Biol Med</em> 1987;60:133&#8211;7.</li>

<li class="Ref">Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine
intake with the risk of Parkinson disease. <em>JAMA</em> 2000;283:2674&#8211;9.</li>

<li class="Ref">Kempster PA, Wahlqvist ML. Dietary factors in the management of
Parkinson&#8217;s disease. <em>Nutr Rev</em> 1994;52:51&#8211;8 [review].</li>

<li class="Ref">Reuter I, Engelhardt M, Stecker K, Baas H. Therapeutic value of exercise
training in Parkinson&#8217;s disease. <em>Med Sci Sports Exerc</em>
1999;31:1544&#8211;9.</li>

<li class="Ref">Corrigan FM, Wienburg CL, Shore RF, et al. Organochlorine insecticides in
substantia nigra in Parkinson&#8217;s disease. <em>J Toxicol Environ Health</em>
2000;59:229&#8211;34.</li>

<li class="Ref">Fleming L, Mann JB, Bean J, et al. Parkinson&#8217;s disease and brain levels
of organochlorine pesticides. <em>Ann Neurol</em> 1994;36:100&#8211;3.</li>

<li class="Ref">Corrigan FM, Murray L, Wyatt CL, Shore RF. Diorthosubstituted polychlorinated
biphenyls in caudate nucleus in Parkinson&#8217;s disease. <em>Exp Neurol</em>
1998;150:339&#8211;42.</li>

<li class="Ref">Ritz B, Yu F. Parkinson&#8217;s disease mortality and pesticide exposure in
California 1984&#8211;1994. <em>Int J Epidemiol</em> 2000;29:323&#8211;9.</li>

<li class="Ref">Geusau A, Tschachler E, Meixner M, et al. Olestra increases faecal excretion
of 2,3,7,8-tetrachlorodibenzo-p-dioxin. <em>Lancet</em> 1999;354:1266&#8211;7.</li>

<li class="Ref">Moser GA, McLachlan MS. A non-absorbable dietary fat substitute enhances
elimination of persistent lipophilic contaminants in humans. <em>Chemosphere</em>
1999;39:1513&#8211;21.</li>

<li class="Ref">Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early
Parkinson disease: evidence of slowing of the functional decline. <em>Arch Neurol</em>
2002;59:1541&#8211;50.)</li>

<li class="Ref">de Rijk MC, Breteler MM, den Breeijen JH, et al. Dietary antioxidants and
Parkinson disease. The Rotterdam Study. <em>Arch Neurol</em> 1997;54:762&#8211;5.</li>

<li class="Ref">Scheider WL, Hershey LA, Vena JE, et al. Dietary antioxidants and other
dietary factors in the etiology of Parkinson&#8217;s disease. <em>Mov Disord</em>
1997;12:190&#8211;6.</li>

<li class="Ref">Molina JA, de Bustos F, Jimenez-Jimenez FJ, et al. Cerebrospinal fluid levels
of alpha-tocopherol (vitamin E) in Parkinson&#8217;s disease. <em>J Neural Transm</em>
1997;104:1287&#8211;93.</li>

<li class="Ref">Federico A, Battisti C, Formichi P, Dotti MT. Plasma levels of vitamin E in
Parkinson&#8217;s disease. <em>J Neural Transm Suppl</em>1995;267&#8211;70.</li>

<li class="Ref">Morens DM, Grandinetti A, Waslien CI, et al. Case-control study of idiopathic
Parkinson&#8217;s disease and dietary vitamin E intake. <em>Neurology</em>
1996;46:1270&#8211;4.</li>

<li class="Ref">Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early
Parkinson&#8217;s disease. <em>Ann Neurol</em> 1992;32:S128&#8211;32.</li>

<li class="Ref">Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study
Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. <em>Ann Neurol</em>
1998;44:S160&#8211;6.</li>

<li class="Ref">Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early
Parkinson&#8217;s disease. <em>Ann Neurol</em> 1992;32:S128&#8211;32.</li>

<li class="Ref">Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study
Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism. <em>Ann Neurol</em>
1998;44:S160&#8211;6.</li>

<li class="Ref">Vatassery GT, Fahn S, Kuskowski MA. Alpha tocopherol in CSF of subjects taking
high-dose vitamin E in the DATATOP study. Parkinson Study Group. <em>Neurology</em>
1998;50:1900&#8211;2.</li>

<li class="Ref">Pappert EJ, Tangney CC, Goetz CG, et al. Alpha-tocopherol in the ventricular
cerebrospinal fluid of Parkinson&#8217;s disease patients: dose-response study and
correlations with plasma levels. <em>Neurology</em> 1996;47:1037&#8211;42.</li>

<li class="Ref">Baker AB. Treatment of paralysis agitans with vitamin B6. <em>JAMA</em>
1941;116:2484.</li>

<li class="Ref">Pfeiffer R, Ebadi M. On the mechanism of the nullification of CNS effects of
L-DOPA by pyridoxine in Parkinsonian patients. <em>J Neurochem</em>
1972;19(9):2175&#8211;81.</li>

<li class="Ref">Leon AS, Spiegel HE, Thomas G, Abrams WB. Pyridoxine antagonism of levodopa in
parkinsonism. <em>JAMA</em> 1971;218(13):1924&#8211;7.</li>

<li class="Ref">Mars H. Metabolic interactions of pyridoxine, levodopa, and carbidopa in
Parkinson&#8217;s disease. <em>Trans Am Neurol Assoc</em> 1973;98:241&#8211;5.</li>

<li class="Ref">Smythies JR, Halsey JH. Treatment of Parkinson&#8217;s disease with
l-methionine. <em>South Med J</em> 1984;77:1577.</li>

<li class="Ref">Bender DA, Earl CJ, Lees AJ. Niacin depletion in Parkinsonian patients treated
with L-dopa, benserizide and carbidopa. <em>Clin Sci</em> 1979;56:89&#8211;93.</li>

<li class="Ref">Cotzias GC, Lawrence WH, Papavasiliou PS, Duby SE. Nicotinamide ineffective in
parkinsonism. <em>N Engl J Med</em> 1972;287:147.</li>

<li class="Ref">Birkmayer JGD, Vrecko C, Volc D, et al. Nicotinamide adenine dinucleotide
(NAD). A new therapeutic approach to Parkinson&#8217;s disease. Comparison of oral and
parenteral application. <em>Neurol Scand</em> 1993;87(Suppl 146):32&#8211;5.</li>

<li class="Ref">Birkmayer JGD. Coenzyme nicotinamide adenine dinucleotide. New therapeutic
approach to improving dementia of the Alzheimers type. <em>Ann Clin Lab Sci</em>
1996;26:1&#8211;9.</li>

<li class="Ref">Wright JV. Interview: Alzheimer&#8217;s, Parkinson&#8217;s, NADH research.
Jorg Birkmayer, M.D. <em>Nutr Healing</em> 1997;May:5&#8211;6.</li>

<li class="Ref">Dizdar N, Kagedal B, Lindvall B. Treatment of Parkinson&#8217;s disease with
NADH. <em>Acta Neurologica Scand</em> 1994;90:345&#8211;7.</li>

<li class="Ref">Mayeux R, Stern Y, Sano M, et al. The relationship of serotonin to depression
in Parkinson&#8217;s disease. <em>Mov Disord</em> 1988;3:237&#8211;44.</li>

<li class="Ref">Bastard J, Truelle JL, Emile J. Effectiveness of 5 hydroxy-tryptophan in
Parkinson&#8217;s disease. <em>Presse Med</em> 1976;5:1836&#8211;7.</li>

<li class="Ref">Sano VI, Taniguchi K. L-5-hydroxytryptophan (L-5-HTP) therapy in
Parkinson&#8217;s disease. <em>MMWR</em> 1972;114:1717&#8211;9.</li>

<li class="Ref">Chase TN, Ng LK, Watanabe AM. Parkinson&#8217;s disease: modification by
5-hydroxytryptophan. <em>Neurology</em> 1972;22:479&#8211;84.</li>

<li class="Ref">Chase TN, Ng LK, Watanabe AM. Parkinson&#8217;s disease. Modification by
5-hydroxytryptophan. <em>Neurology</em> 1972;22:479&#8211;84.</li>

<li class="Ref">Mendlewicz J, Youdim MB. Antidepressant potentiation of 5-hydroxytryptophan by
L-deprenil in affective illness. <em>J Affect Disord</em> 1980;2:137&#8211;46.</li>

<li class="Ref">Wurtman RJ, Wurtman JJ, eds. <em>Nutrition and the Brain,</em> vol 7. New
York: Raven Press, 1986.</li>

<li class="Ref">Lemoine P, Robelin N, Sebert P, Mouret J. L-tyrosine: a long term treatment of
Parkinson&#8217;s disease. <em>C R Acad Sci III</em> 1989;309:43&#8211;7.</li>

<li class="Ref">Heller B, Fischer E, Martin R. Therapeutic action of D-phenylalanine in
Parkinson&#8217;s disease. <em>Arzneimittelforschung</em> 1976;26:577&#8211;9.</li>

<li class="Ref">Wurtman RJ, Wurtman JJ, eds. <em>Nutrition and the Brain,</em> vol 7. New
York: Raven Press, 1986.</li>

<li class="Ref">Riekkinen P, Rinne UK, Pelliniemi TT, Sonninen V. Interaction between dopamine
and phospholipids. Studies of the substantia nigra in Parkinson disease patients. <em>Arch
Neurol</em> 1975;32:25&#8211;7.</li>

<li class="Ref">Funfgeld EW, Baggen M, Nedwidek P, et al. Double-blind study with
phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer&#8217;s
type (SDAT). <em>Prog Clin Biol Res</em> 1989;317:1235&#8211;46.</li>

<li class="Ref">Gaby AR. Don&#8217;t believe everything you read. <em>Townsend Letter for
Doctors and Patients</em> 1997;July:125&#8211;6.</li>

<li class="Ref">Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and
reduced bone mass in Parkinson&#8217;s disease. <em>Neurology</em> 1997;49:1273&#8211;8.</li>

<li class="Ref">Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and
reduced bone mass in Parkinson&#8217;s disease. <em>Neurology</em>1997;49:1273&#8211;8.</li>

<li class="Ref">Sato Y, Manabe S, Kuno H, Oizumi K. Amelioration of osteopenia and
hypovitaminosis D by 1 a-hydroxyvitamin D3 in elderly patients with Parkinson&#8217;s disease.
<em>J Neurol Neurosurg Psychiatry</em> 1999;66:64&#8211;8.</li>

<li class="Ref">Forsleff L, Schauss AG, Bier ID, et al. Evidence of functional zinc deficiency
in Parkinson&#8217;s disease. <em>J Altern Complement Med</em> 1999;5:57&#8211;64.</li>

<li class="Ref">Uitti RJ, Rajput AH, Rozdilsky B, et al. Regional metal concentrations in
Parkinson&#8217;s disease, other chronic neurological diseases, and control brains. <em>Can J
Neurol Sci</em> 1989;16:310&#8211;4.</li>

<li class="Ref">Pall HS, Williams AC, Blake DR, et al. Raised cerebrospinal fluid copper
concentration in Parkinson&#8217;s disease. <em>Lancet</em> 1987;2(8553):238&#8211;41.</li>

<li class="Ref">Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron,
ferritin and other trace metals in Parkinson&#8217;s disease and other neurodegenerative
diseases affecting the basal ganglia. <em>Brain</em> 1991;114:1953&#8211;75.</li>

<li class="Ref">Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron,
ferritin and other trace metals in Parkinson&#8217;s disease and other neurodegenerative
diseases affecting the basal ganglia. <em>Brain</em> 1991;114:1953&#8211;75.</li>

<li class="Ref">Pall HS, Williams AC, Blake DR, et al. Raised cerebrospinal fluid copper
concentration in Parkinson&#8217;s disease. <em>Lancet</em> 1987;2(8553):238&#8211;41.</li>

<li class="Ref">An alternative medicine treatment for Parkinson&#8217;s disease: results of a
multicenter clinical trial. HP-200 in Parkinson&#8217;s Disease Study Group. <em>J Altern
Complement Med</em> 1995;1:249&#8211;55.</li>

<li class="Ref">Ashraf W, Pfeiffer RF, Park F, et al. Constipation in Parkinson&#8217;s
disease: objective assessment and response to psyllium. <em>Mov Disord</em>
1997;12:946&#8211;51.</li>
</ol>
</div>
</body>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Concern/Parkinsons_Disease.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:31:06 GMT -->
</html>

